MCF7-VHL-KO Cell Line

The Von Hippel-Lindau (VHL) gene, located on the short arm of chromosome 3 (3p25-26), is a crucial tumor suppressor gene. Its primary function is to regulate cellular responses to oxygen levels. The VHL protein (pVHL) forms part of an E3 ubiquitin ligase complex that targets the alpha subunit of hypoxia-inducible factor (HIF-1α and HIF-2α) for proteasomal degradation under normoxic conditions. This prevents the inappropriate activation of hypoxia-responsive genes involved in angiogenesis (e.g., VEGF), erythropoiesis (e.g., EPO), and glucose metabolism. Germline mutations in the VHL gene cause Von Hippel-Lindau syndrome (VHL disease), an autosomal dominant hereditary cancer predisposition syndrome (OMIM #193300). Individuals with VHL disease develop multiple benign and malignant tumors in various organs, including the central nervous system (hemangioblastomas), retina, kidneys (clear cell renal cell carcinoma), adrenal glands (pheochromocytomas), pancreas (cysts and neuroendocrine tumors), and endolymphatic sac. The disease follows Knudson's "two-hit" hypothesis, requiring inactivation of both alleles for tumorigenesis. Loss of functional pVHL leads to constitutive HIF stabilization, even under normal oxygen tension, driving uncontrolled expression of pro-growth and pro-angiogenic factors. Understanding VHL biology is fundamental for diagnosing VHL syndrome and developing targeted therapies for associated cancers.